ANAB

AnaptysBio Inc

Add to Watchlist

Advanced Chart

22.540

-1.15(-4.854%)1D

Overview
Forecast
Valuation
Earnings

Line

Candle

YTD

High

23.935

Open

23.300

VWAP

22.73

Vol

474.19K

Mkt Cap

662.24M

Low

22.400

Amount

10.78M

EV/EBITDA(TTM)

Total Shares

27.32M

356.09M

EV/OCF(TTM)

P/S(TTM)

6.21

AnaptysBio, Inc. is a clinical-stage biotechnology company. The Company is focused on delivering immunology therapeutics for autoimmune and inflammatory diseases. The Company’s lead program, Rosnilimab, is a depleter and agonist targeting PD-1+ T cells, is in a Phase IIb trial for the treatment of rheumatoid arthritis and in a Phase II trial for the treatment of ulcerative colitis. The Company’s pipeline also includes ANB033, a CD122 antagonist, and ANB101, a blood dendritic cell antigen 2 (BDCA2) modulator, in Phase I trials. It has also discovered multiple therapeutic antibodies licensed to GSK in a financial collaboration for immuno-oncology, including a PD-1 antagonist (Jemperli (dostarlimab-gxly)) and a TIM-3 antagonist (cobolimab, GSK4069889). Rosnilimab is an IgG1 antibody that directly targets PD-1+ T cells, resulting in their depletion or agonism, impacting pathogenic drivers of autoimmune and inflammatory diseases.

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q2

FY2025Q3

FY2025Q4

11.68M

+6.5%

-1.546

-9.58%

11.76M

-60.81%

-1.534

+34.56%

28.32M

-34.32%

-1.161

+61.23%

Estimates Revision

The market is revising Upward the revenue expectations for AnaptysBio, Inc. (ANAB) for FY2025, with the revenue forecasts being adjusted by 24.1% over the past three months. During the same period, the stock price has changed by 14.53%.

Revenue Estimates for FY2025

Revise Upward

+24.1%

In Past 3 Month

EPS Estimates for FY2025

Revise Downward

-2.52%

In Past 3 Month

Stock Price

Go Up

+14.53%

In Past 3 Month

11 Analyst Rating

125.64% Upside

Wall Street analysts forecast ANAB stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ANAB is 50.86 USD with a low forecast of 25.00 USD and a high forecast of 90.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

10 Buy

1 Hold

0 Sell

Strong Buy

125.64% Upside

Current: 22.540

Low

25.00

Averages

50.86

High

90.00

125.64% Upside

Current: 22.540

Low

25.00

Averages

50.86

High

90.00

JPMorgan

Overweight

maintain

2025-06-11

Reason

JPMorgan

Price Target

2025-06-11

maintain

Overweight

Reason

JPMorgan says AnaptysBio shares at current levels are undervalued on the clinical and strategic potential of rosnilimab in rheumatoid arthritis alone. Looking to the balance of the year, the firm expects an increasing focus on the potential of the asset in ulcerative colitis, given the anticipated Q4 Phase 2 data. JPMorgan does not sense there are any Street expectations for the ulcerative colitis Phase 2 readout. While the company did not provide more granular details on timing, AnaptysBio noted a clear line of sight on enrollment completion, so the timelines are not at risk, the analyst tells investors in a research note. JPMorgan keeps an Overweight rating on AnaptysBio.

H.C. Wainwright

Neutral -> Buy

upgrade

$38

2025-06-04

Reason

H.C. Wainwright

Price Target

$38

2025-06-04

upgrade

Neutral -> Buy

Reason

H.C. Wainwright upgraded AnaptysBio to Buy from Neutral with a $38 price target after the company announced week 28 data from the Phase 2 rheumatoid arthritis trial which met its primary endpoint. The firm says that given the data "showcase a positive holistic story" for rosnilimab in rheumatoid arthritis, it is increasingly positive on upcoming ulcerative colitis data. AnaptysBio's week 28 data compare favorably with competitor datasets, such as JAK inhibitors, contends H.C. Wainwright.

Guggenheim

NULL -> Buy

maintain

$54 -> $90

2025-05-28

Reason

Guggenheim

Price Target

$54 -> $90

2025-05-28

maintain

NULL -> Buy

Reason

Guggenheim raised the firm's price target on AnaptysBio (ANAB) to $90 from $54 and keeps a Buy rating on the shares. The firm is "encouraged" by the company's ongoing clinical developments and strong financial position and believes the stock is trading at a significant discount, says the analyst, who updated the firm's model to reflect GSK's (GSK) Jemperli royalties.

JP Morgan

Anupam Rama

Buy

Maintains

$36 → $42

2025-03-05

Reason

JP Morgan

Anupam Rama

Price Target

$36 → $42

2025-03-05

Maintains

Buy

Reason

JPMorgan raised the firm's price target on AnaptysBio to $42 from $36 and keeps an Overweight rating on the shares. The firm updated models in the Smid-cap biotechnology group.

HC Wainwright & Co.

Emily Bodnar

Hold

Reiterates

$22

2025-03-04

Reason

HC Wainwright & Co.

Emily Bodnar

Price Target

$22

2025-03-04

Reiterates

Hold

Reason

Wells Fargo

Derek Archila

Buy

Maintains

$40 → $51

2025-02-13

Reason

Wells Fargo

Derek Archila

Price Target

$40 → $51

2025-02-13

Maintains

Buy

Reason

See All Ratings

Valuation Metrics

The current forward P/E ratio for AnaptysBio Inc (ANAB.O) is -4.36, compared to its 5-year average forward P/E of -4.22. For a more detailed relative valuation and DCF analysis to assess AnaptysBio Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-4.22

Current PE

-4.36

Overvalued PE

2.59

Undervalued PE

-11.03

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-2.36

Current EV/EBITDA

-6.70

Overvalued EV/EBITDA

1.63

Undervalued EV/EBITDA

-6.35

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

Fair

5Y Average PS

29.39

Current PS

11.53

Overvalued PS

54.27

Undervalued PS

4.50

Financials

Annual

Quarterly

FY2025Q2

YoY :

+102.93%

22.26M

Total Revenue

FY2025Q2

YoY :

-35.10%

-26.17M

Operating Profit

FY2025Q2

YoY :

-17.21%

-38.63M

Net Income after Tax

FY2025Q2

YoY :

-21.64%

-1.34

EPS - Diluted

FY2025Q2

YoY :

+88.63%

-40.28M

Free Cash Flow

FY2025Q2

YoY :

-100.00%

N/A

Gross Profit Margin - %

FY2025Q2

YoY :

-75.61%

-103.99

FCF Margin - %

FY2025Q2

YoY :

-100.00%

N/A

Net Margin - %

Trading Trends

Insider

Insiders areSelling! The selling amount has increased 241.21% over the last month.

Sold

0-3

Months

637.7K

USD

3-6

Months

0.0

USD

6-9

Months

0.0

USD

0-12

Months

1.4M

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

1.1M

USD

Months

0-12

0.0

USD

Months

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

0-3

Months

0.0

Volume

3-6

Months

812.0K

Volume

6-9

Months

714.7K

Volume

0-12

Months

0.0

Volume

Bought

0-3

0.0

Volume

Months

3-6

4.8M

Volume

Months

6-9

5.0M

Volume

Months

0-12

274.0K

Volume

Months

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

0.0

USD

6-9

Months

0.0

USD

0-12

Months

0.0

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

Insider

Insiders areSelling! The selling amount has increased 241.21% over the last month.

Sold

0-3

Months

637.7K

USD

3-6

Months

0.0

USD

6-9

Months

0.0

USD

0-12

Months

1.4M

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

1.1M

USD

Months

0-12

0.0

USD

Months

ANAB News & Events

Events Timeline

2025-06-04 (ET)

2025-06-04

12:58:14

AnaptysBio's rosnilimab demonstrates safety in Phase 2b trial, says Leerink

2025-06-03 (ET)

2025-06-03

16:29:24

AnaptysBio announces investigational rosnilimab data

2025-05-05 (ET)

2025-05-05

17:02:54

AnaptysBio reports Q1 EPS ($1.28), consensus ($1.46)

News

9.0

06-04SeekingAlpha

J&J sends AnaptysBio lower with mid-stage trial data for anti-inflammatory agent

4.0

06-04Benzinga

This Snowflake Analyst Turns Bullish; Here Are Top 5 Upgrades For Wednesday

9.0

06-04SeekingAlpha

Anaptys gains after updated data from mid-stage trial for arthritis therapy

People Also Watch

CHPT

ChargePoint Holdings Inc

Xeris Biopharma Holdings Inc

Bar Harbor Bankshares

Global Indemnity Group LLC

Entrada Therapeutics Inc

Phathom Pharmaceuticals Inc

Greenfire Resources Ltd

Bigcommerce Holdings Inc

FAQ

What is AnaptysBio Inc (ANAB) stock price today?

The current price of ANAB is 22.54 USD — it has decreased -4.85 % in the last trading day.

ANAB

Market Estimates

Valuation Metrics

Forward PE

Forward EV/EBITDA

Forward PS

Financials

Trading Trends

ANAB News & Events

Events Timeline

News

People Also Watch

FAQ

What is AnaptysBio Inc (ANAB) stock price today?

What is AnaptysBio Inc (ANAB)'s business?

What is the price predicton of ANAB Stock?

What is AnaptysBio Inc (ANAB)'s revenue for the last quarter?

What is AnaptysBio Inc (ANAB)'s earnings per share (EPS) for the last quarter?

What changes have occurred in the market's expectations for AnaptysBio Inc (ANAB)'s fundamentals?

How many employees does AnaptysBio Inc (ANAB). have?

What is AnaptysBio Inc (ANAB) market cap?